GlassScriptPhysician profile
Jacqueline M Hanson
NPI 1790221034
$3,875.74
in general payments reported to CMS, 2019-2025
22 companies · $1,366 in 2025
The $1,366 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.60 · 2023: $942 · 2024: $1,534 · 2025: $1,366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,842.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $848.99 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $525.69 | 2023-2025 | Trelegy Ellipta, Nucala, Shingrix |
| United Therapeutics Corporation | $431.61 | 2023-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.45 | 2024-2025 | Ofev |
| Inspire Medical Systems, INC. | $236.28 | 2023 | Inspire |
| Paratek Pharmaceuticals, INC. | $189.88 | 2024-2025 | Nuzyra |
| Genzyme Corporation | $160.21 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $153.67 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.54 | 2024-2025 | Dupixent |
| Amgen INC. | $148.97 | 2023-2025 | Tezspire |
| Abbvie INC. | $145.98 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.83 | 2023-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $117.05 | 2024-2025 | Purified Cortrophin Gel |
| Tactile Systems Technology INC | $60.33 | 2025 | Nimbl, Flexitouch Plus |
| Melinta Therapeutics, LLC | $45.07 | 2024-2025 | Rezzayo, Kimyrsa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $33.64 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $28.82 | 2024 | Yupelri |
| Verona Pharma, INC. | $28.07 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $27.29 | 2025 | Opsynvi |
| Viiv Healthcare Company | $25.60 | 2025 | Apretude |
| Merck Sharp & Dohme LLC | $15.69 | 2024 | Winrevair |
| Lilly USA, LLC | $15.08 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.